stockrowGlobus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
Follow GMED
Alert me
Globus Medical, Inc. (GMED) EPS (diluted)
Globus Medical, Inc.'s EPS (diluted) for fiscal 2025 was $3.92, up 422.7% from $0.75 in fiscal 2024. Over the twelve months to 30 September 2026 it was $4.07. Over the past ten years it has ranged from $0.75 (fiscal 2024) to $3.92 (fiscal 2025) — the current reading is the highest in ten years. Globus Medical, Inc. ranks 8th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.92 | 422.67% |
| FY2024 | $0.75 | (29.91%) |
| FY2023 | $1.07 | (42.16%) |
| FY2022 | $1.85 | 28.47% |
| FY2021 | $1.44 | 42.57% |
| FY2020 | $1.01 | (33.55%) |
| FY2019 | $1.52 | (1.30%) |
| FY2018 | $1.54 | 40.00% |
| FY2017 | $1.10 | 1.85% |
| FY2016 | $1.08 | (7.69%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.04 | (5.45%) |
| Jun 2026 | $1.10 | 22.22% |
| Mar 2026 | $0.90 | (12.62%) |
| Dec 2025 | $1.03 | 17.05% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| PODD Insulet Corporation compare | $6.14 |
| GMED Globus Medical, Inc. | $4.07 |
| PEN Penumbra, Inc. compare | $3.97 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| TXG 10x Genomics compare | −$0.59 |
| BRKR Bruker Corporation compare | −$1.01 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GMED
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement